LUND, SE / ACCESS Newswire / April 29, 2025 / BioInvent International (STO:BINV)
"The first quarter of 2025 was a highly productive period across clinical development, regulatory milestones, and strategic partnerships - positioning us for strong momentum through the remainder of the year."- Martin Welschof CEO of BioInvent.
EVENTS IN THE FIRST QUARTER
(R) Positive initial efficacy data from Phase 2a trial of triple combination of the company's lead anti-FcyRIIB antibody BI-1206, rituximab and Calquence ® for the treatment of non-Hodgkin's Lymphoma (NHL)
(R) Phase 1 data of the company's second anti-TNFR2 antibody BI-1910 as monotherapy for the treatment of solid tumors
BioInvent achieved ISO 26000 Verification, highlighting commitment to ESG and transparency
Composition of matter patent for the lead anti-TNFR2 antibody BI-1808 granted in Japan. It also covers the use of the antibody in the treatment of cancer
BI-1808 received Orphan Drug Designation from FDA for the treatment of T-cell lymphoma
BI-1808 showcased at the 16th Annual T-Cell Lymphoma Forum
EVENTS AFTER THE END OF THE PERIOD
BioInvent received milestone payment as Takeda moved mezagitamab into Phase 3
(R)= Regulatory event
FINANCIAL INFORMATION
First quarter 2025
Net sales SEK 22.1 (5.9) million.
Profit/loss after tax SEK -116.6 (-77.9) million.
Profit/loss after tax per share before and after dilution SEK -1.77 (1.18).
Cash flow from operating activities SEK -120.0 (-65.9) million.
Liquid funds, current and long-term investments at the end of the period SEK 742.2 (1,219.2) million.
The complete interim report is available for download below and on the company's website under Financial reports .
About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates in six ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors. The Company's validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory drug candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com .
For further information, please contact:
Cecilia Hofvander, VP Investor Relations
Phone: +46 (0)46 286 85 50
Email: cecilia.hofvander@bioinvent.com
BioInvent International AB (publ)
Co. Reg. No.: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com
Attachments
SOURCE: BioInvent International
View the original press release on ACCESS Newswire
